GO
Loading...

Actavis Inc

More

  • American Airlines to join S&P 500 Monday, 16 Mar 2015 | 6:56 PM ET

    NEW YORK— S&P Dow Jones Indices says that American Airlines Group will soon be joining the S&P 500 index. The Fort Worth, Texas, holding company for American Airlines and US Airways will be added to the index after the close of trading on Friday. American Airlines is replacing health care company Allergan, which is being acquired by Actavis in a deal expected to...

  • Valeant ups Salix bid to $11.11B and Endo ends quest Monday, 16 Mar 2015 | 8:23 AM ET

    Valeant raised its offer for Salix Pharmaceuticals Ltd. by more than $1 billion Monday, forcing rival bidder Endo International out of the running. Canada's Valeant Pharmaceuticals International Inc. said it would pay $11.11 billion in cash, or $173 per share, a 2 percent premium over Friday's closing price. On Monday, Allergan said that its acquisition by...

  • Ackman's $20 billion Pershing Square Capital Management hedge fund began building up the $3.3 billion stake, only months after its vocal effort to help Valeant buy Botox-maker Allergan failed, a source familiar with the investment told Reuters. His Pershing Square has notched big wins at railway firm Canadian Pacific and shopping mall operator General...

  • Ackman's $20 billion Pershing Square Capital Management began building up the 5 percent stake in the Canadian drug maker this year, only months after his vocal effort to help Valeant buy Botox-maker Allergan failed. His Pershing Square has notched big wins at railway Canadian Pacific and shopping mall operator General Growth Properties, and also made money...

  • *Brent crude ends above $61 on conflict in Libya. NEW YORK, March 3- U.S. stocks followed other equities markets lower on Tuesday, with major indexes pulling back from record highs as soft auto sales raised doubts about the U.S. economy, while the dollar fell from an 11- year peak versus a basket of currencies. "The air gets a little thin up at new highs and you need a driver...

  • *Actavis launches $21 billion bond deal. *Exxon Mobil to sell $7 billion in debt. Pharmaceutical company Actavis Plc launched a $21 billion corporate bond deal, the second-largest on record, according to Thomson Reuters unit IFR.

  • *Brent crude climbs near $61 on conflict in Libya. NEW YORK, March 3- U.S. stock prices fell on Tuesday, with the Dow Jones industrial average and the Standard& Poor's 500 pulling back from record highs, while the dollar fell from an 11- year peak versus a basket of currencies. "The air gets a little thin up at new highs and you need a driver to keep it going, and one of the...

  • *Actavis launches $21 bln bond deal. *Exxon Mobil to sell $7 bln in debt. Pharmaceutical company Actavis Plc launched a $21 billion corporate bond deal, the second-largest on record according to Thomson Reuters unit IFR.

  • *Brent crude climbs above $61 on conflict in Libya. NEW YORK, March 3- U.S. stock prices fell on Tuesday, with the Dow Jones industrial average and Standard& Poor's 500 receding from their record highs, while the dollar fell from its 11- year peak versus a basket of currencies. "The market is naturally settling in, taking a breather until the scales tip either way to...

  • NEW YORK, March 2- U.S. Pharmaceutical company Actavis on Monday was marketing bonds that are expected to total $22 billion, the second largest amount ever sold by a corporate borrower. "Corporate deals are weighing on the market, and we've heard of some allocation out of bonds into equities," said Sean Murphy, a Treasuries trader at Societe Generale in New York.

  • Dublin- based Actavis Plc holds the commercial license for the product, but the marketing application was submitted by non-profit pharmaceutical company Medicines360, which holds the U.S. public sector clinic rights. The companies expect the device, which also helps to check heavy menstrual bleeding, to be available in the United States by the second quarter...

  • Actavis Plc holds the commercial license to the device, Liletta. Actavis and Medicines360 expect the device to be available for use in the United States by the second quarter of 2015.. The Actavis device will compete in the $1 billion global market for UIDs, said Michael WaterHouse, an analyst at brokerage Morningstar.

  • Actavis' contraceptive device wins U.S. FDA approval Friday, 27 Feb 2015 | 8:10 AM ET

    Feb 27- The U.S. Food and Drug Administration said on Friday it approved a hormonal contraceptive device, providing American women another reversible contraceptive choice as effective as sterilization. Actavis Plc holds the commercial license to the device, the marketing application of which was submitted by non-profit pharmaceutical company...

  • Feb 25- The U.S. Food and Drug Administration on Wednesday approved the use of Actavis Plc's antibiotic, Avycaz, to battle drug-resistant bacteria known as superbugs. Although a number of companies including Roche Holdings AG, Tetraphase Pharmaceuticals Inc, Achaogen Inc and Cempra Inc, are developing drugs for a variety of superbugs, Gabelli& Co analyst Kevin...

  • UPDATE 1-Actavis' superbug antibiotic gets U.S. approval Wednesday, 25 Feb 2015 | 7:50 PM ET

    Feb 25- The U.S. Food and Drug Administration on Wednesday approved the use of Actavis Plc's antibiotic, Avycaz, to battle drug-resistant bacteria known as superbugs. Although a number of companies including Roche Holdings AG, Tetraphase Pharmaceuticals Inc, Achaogen Inc and Cempra Inc, are developing drugs for a variety of superbugs, Gabelli& Co analyst Kevin...

  • TOKYO, Feb 20- Activist investor Daniel Loeb said Fanuc Corp's plan to boost investments was not enough to fix its "blatant capital inefficiency", stepping up calls for the Japanese industrial robot maker to reward shareholders through major buybacks. Loeb, whose hedge fund Third Point holds an undisclosed stake in Fanuc, told Reuters by email the plan to double...

  • NEW YORK, Feb 18- Actavis Plc, a generic drugmaker that has been steadily acquiring branded medicines, said it will change its name to Allergan Inc after it completes its planned $66 billion purchase of the Botox maker, signaling its growing focus on patent-protected drugs. Actavis, which began as a New Jersey- based generics company called Watson, took its current...

  • UPDATE 2-Actavis beats profit estimates, raises forecast Wednesday, 18 Feb 2015 | 9:11 AM ET

    Feb 18- Actavis Plc posted a better-than-expected adjusted quarterly profit and raised its full-year earnings forecast, saying it expected strong sales of its new branded drugs. Actavis agreed to buy Allergan Inc last November for $66 billion, outbidding a hostile offer by activist investor William Ackman and Valeant Pharmaceuticals International Inc.

  • Actavis, which bought Botox-maker Allergan Inc in November, makes drugs from research in its own pipeline, and copy cat versions of other popular drugs. Sales of the Actavis's branded drugs nearly tripled to $1.83 billion in North America in the fourth quarter, accounting for 45 percent of total revenue. For the fourth quarter ended Dec. 31, Actavis's net loss...

  • *Deal builds on last year's purchase of Almirall drugs. LONDON, Feb 5- AstraZeneca has agreed to buy Actavis' branded respiratory drug business in the United States and Canada for an initial $600 million as it seeks external deals to ensure growth. AstraZeneca will also pay another $100 million, after Actavis agreed to a number of changes to ongoing agreements...